Pieris Pharmaceuticals (NASDAQ:PIRS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note published on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

PIRS opened at $13.60 on Friday. The stock has a market capitalization of $17.95 million, a PE ratio of -1.12 and a beta of 0.61. The stock’s 50 day moving average price is $15.24 and its 200-day moving average price is $15.04. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $22.32.

Institutional Investors Weigh In On Pieris Pharmaceuticals

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. BML Capital Management LLC purchased a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals accounts for approximately 0.4% of BML Capital Management LLC’s portfolio, making the stock its 21st largest position. BML Capital Management LLC owned 3.19% of Pieris Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.